GERN - Geron lead asset approved in the U.S. for blood cancer
2024-06-06 22:31:45 ET
More on Geron
- Geron Corporation: A High-Risk Deal With A Good Chance Of Success
- Geron Corporation (GERN) Q1 2024 Earnings Call Transcript
- Geron: FDA PDUFA Review With Continued Imetelstat Advancement
- Geron GAAP EPS of -$0.09 beats by $0.01
- Geron Q1 2024 Earnings Preview